MATN1 and acute myeloid leukemia: Early SLA (i.e., MPP-L and CMP-L, 31 AML, 209 mice) had higher number of engrafted mice (64.4% vs. 23.5%, p = 0.0001, Fig. 3B), higher levels of engraftment (21.5% vs. 4.7%, p = 0.0027, Fig. 3C), and greater expansion of leukemic cells (1.9 vs. 0.2-fold, p = 0.0002, Fig. 3D) than late SLA (GMP-L, MP-L, and GP-L, 38 AML, 237 mice).